T

TriSalus Life Sciences Inc
NASDAQ:TLSI

Watchlist Manager
TriSalus Life Sciences Inc
NASDAQ:TLSI
Watchlist
Price: 4.13 USD 1.72% Market Closed
Market Cap: 125.9m USD
Have any thoughts about
TriSalus Life Sciences Inc?
Write Note

TriSalus Life Sciences Inc
Free Cash Flow

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

TriSalus Life Sciences Inc
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
T
TriSalus Life Sciences Inc
NASDAQ:TLSI
Free Cash Flow
-$50.6m
CAGR 3-Years
-321%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
N
Nextdoor Holdings Inc
NYSE:KIND
Free Cash Flow
-$59.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Flame Acquisition Corp
NYSE:SOC
Free Cash Flow
-$3.8m
CAGR 3-Years
-1 824%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Core Scientific Inc
NASDAQ:CORZ
Free Cash Flow
$48.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Symbotic Inc
NASDAQ:SYM
Free Cash Flow
-$100.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Rumble Inc
NASDAQ:RUM
Free Cash Flow
-$110.4m
CAGR 3-Years
-1 667%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

TriSalus Life Sciences Inc
Glance View

Market Cap
125.8m USD
Industry
N/A

TriSalus Life Sciences Inc is a US-based company operating in industry. The company is headquartered in Westminster, Colorado. The company went IPO on 2020-12-18. TriSalus Life Sciences, Inc. is an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors. The Company’s platform includes devices that utilize a drug delivery technology and a clinical-stage investigational immunotherapy. The Company’s two FDA-cleared devices use its Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. SD-101, the Company’s investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment. Patient data generated during Pressure-Enabled Regional Immuno-Oncology (PERIO) clinical trials support the hypothesis that SD-101 delivered through PEDD may has favorable immune effects on the liver and systemically.

TLSI Intrinsic Value
3.66 USD
Overvaluation 11%
Intrinsic Value
Price
T

See Also

What is TriSalus Life Sciences Inc's Free Cash Flow?
Free Cash Flow
-50.6m USD

Based on the financial report for Dec 31, 2023, TriSalus Life Sciences Inc's Free Cash Flow amounts to -50.6m USD.

What is TriSalus Life Sciences Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 3Y
-321%

Over the last year, the Free Cash Flow growth was -1 748%. The average annual Free Cash Flow growth rates for TriSalus Life Sciences Inc have been -321% over the past three years .

Back to Top